Sign up Australia
Proactive Investors - Run By Investors For Investors

Medlab Clinical to start Australia’s first trial of cannabis for oncology patients

Cannabis will be incorporated with Medlab’s medicine delivery system.
Medlab Clinical to start Australia’s first trial of cannabis for oncology patients
Ethics approval from Royal North Shore Hospital expected soon

Medlab Clinical (ASX:MDC) is completing the final steps to start Australia’s first clinical trial using cannabis for oncology patients suffering intractable pain.

The company’s efforts have been supported by the federal government’s recent announcement to facilitate faster supply of medicinal cannabis products.

Medlab recently obtained clearances from Australian health departments and is awaiting a final shipment clearance from Canadian health authorities to import cannabis material from Canada.

The cannabis material is a combination of the two most active cannabis ingredients, formulated by Medlab and being supplied by Canadian licenced producer of medical marijuana, Aphria Inc.

Medlab has arranged the delivery of the cannabis material to a contractor in Melbourne, licenced for controlled substance manufacture.

The cannabis material will be incorporated with Medlab’s small particle medicine delivery system, Nanocelle™, to be readied for the trial.

In conjunction with the manufacturer, Medlab has established a drug manufacturing method that will be the prescribed template for future production.

Prerequisites for trial commencement are ethics approval from Royal North Shore Hospital, which is progressing well, and the issue of a clinical trial number from Therapeutic Goods Administration.

Importantly, the supportive government attitude towards cannabis is encouraging for the future prospects of Medlab’s initiative with cannabis.

The company’s share price has more than doubled during the past six months, last trading at $0.755.

Medlab  is well funded with a cash balance of $4.3 million as at 31 December 2016.

Register here to be notified of future MDC Company articles
View full MDC profile View Profile

Medlab Clinical Timeline

Related Articles

January 19 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use